Durable tumor control remains out of reach for most dogs with melanoma, and a new review published in The Veterinary Journal pins a major share of the blame on the immunosuppressive tumor microenvironment (TME) that blunts both checkpoint inhibitors and cancer vaccines.

The review, available online 6 October 2026 (Article 106919, DOI: 10.1016/j.tvjl.2026.106919), comes from authors E. Hindriks, M.M.J.M. Zandvliet, A.J.A.M. Sijts and F. Broere, and is published open access under a Creative Commons license. It synthesizes current evidence on the canine TME and evaluates immunotherapeutic and receptor tyrosine kinase (RTK)-targeted strategies in canine cancers, with melanoma as the central model.

Why does the tumor microenvironment matter at the exam table?

The authors lay out the key immune players in canine tumor progression and immune evasion: T cells, B cells, natural killer cells, tumor-associated macrophages and myeloid-derived suppressor cells. Their central argument is practical. Tumor heterogeneity, an immunosuppressive TME and therapeutic resistance are difficult to overcome, and the result is limited clinical efficacy for single-agent approaches that look promising on paper.

For clinicians, that translates into an explanation for why an aggressive, immunogenic tumor like canine melanoma — historically a candidate for immunotherapeutic intervention — still frequently escapes durable control.

What therapeutic classes does the review evaluate?

The review assesses three broad strategies in canine cancers:

• Immune checkpoint inhibitors (ICIs), whose activity is constrained by the immunosuppressive TME
• Therapeutic cancer vaccines, limited by the same microenvironmental barriers
• Receptor tyrosine kinase-targeted therapies, which the authors position as potential support for immunotherapeutics rather than standalone answers

The headline conclusion: combination therapies may improve durable antitumour responses. RTK-based therapies can support immunotherapeutics, and integrating human and veterinary oncology insights may accelerate translational success.

Why canine melanoma specifically?

The review frames canine melanoma as a valuable translational model for cancer therapy research. Naturally occurring cancers in dogs share significant clinical, molecular and genetic similarities with human malignancies, and the authors argue this comparative oncology route could speed development of effective combination therapies for both species.

That dual framing matters. Cancer poses a substantial health burden in both humans and dogs, yet translation of novel targeted therapies and immunotherapies into both human and veterinary oncology has been slow. The dog with spontaneous melanoma offers a trial population that behaves more like human disease than induced rodent models.

What are the caveats?

The paper is a review, not a clinical trial. No new data were generated or analyzed in support of the work. The authors do not report new efficacy figures for any agent; instead they evaluate the existing evidence base and identify the barriers — tumor heterogeneity, immunosuppressive TMEs, therapeutic resistance — that have kept clinical results modest despite promising mechanistic rationale.

For practitioners managing canine melanoma, the review's value lies in organizing why monotherapies underdeliver and where the field is heading: rational combinations pairing checkpoint blockade or vaccines with RTK-targeted agents, designed with the TME in mind rather than around it.

The authors close on a forward note grounded in their comparative thesis: integrating insights from human and veterinary oncology underscores the potential to improve translational success and develop more effective combination therapies for both species.